Clinical Trial

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2022-04-29; most recent amendment 2026-06-10.
Status change: Not Yet Recruiting → Recruiting 2022-05-31
Trial Details
NCT Number NCT05361174
Lead Sponsor Iovance Biotherapeutics, Inc.
Conditions Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Enrollment 53 participants
Start Date 2022-07-20
Primary Completion 2027-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-11